The 2nd Department of Infectious Diseases, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
PLoS One. 2012;7(9):e45202. doi: 10.1371/journal.pone.0045202. Epub 2012 Sep 28.
Glycogen synthase kinase 3β(GSK3β) is a ubiquitous serine-threonine protein kinase that participates in numerous cellular processes and disease pathophysiology. We aimed to determine therapeutic potential of GSK3β inhibition and its mechanism in a well-characterized model of lipopolysaccharide (LPS)-induced model of acute liver failure (ALF).
In a murine ALF model induced by D-GalN(700 mg/kg)/LPS(10 µg/kg), we analyzed GSK3β mechanisms using a specific chemical inhibitor, SB216763, and detected the role of endoplasmic reticulum stress (ERS). Mice were administered SB216763 at 2 h before or after D-GalN/LPS injection, respectively, and then sacrificed 6 h after D-GalN/LPS treatment to evaluate its prophylactic and therapeutic function. The lethality rate, liver damage, ERS, cytokine expression, MAP kinase, hepatocyte apoptosis and expression of TLR 4 were evaluated, respectively. Whether the inhibition of GSK3β activation protected hepatocyte from ERS-induced apoptosis was investigated in vitro.
GSK3β became quickly activated (dephosphorylated) upon D-GalN/LPS exposure. Administration of SB216763 not only ameliorated liver injury, as evidenced by reduced transaminase levels, and well-preserved liver architecture, but also decreased lethality. Moreover, GSK3β inhibition resulted in down-regulation of pro-apoptotic proteins C/EBP-homologous protein(CHOP) and caspase-12, which are related to ERS. To further demonstrate the role of ERS, we found that GSK3β inhibition protected hepatocyte from ERS-induced cell death. GSK3β inhibition down-regulated the MAPK pathways, reduced expression of inflammatory cytokines and decreased expression of TLR4.
Our findings demonstrate the key function of GSK3β signaling in the pathophysiology of ALF, especially in regulating the ERS, and provide a rationale for targeting GSK3β as a potential therapeutic strategy to ameliorate ALF.
糖原合酶激酶 3β(GSK3β)是一种普遍存在的丝氨酸/苏氨酸蛋白激酶,参与多种细胞过程和疾病病理生理学。我们旨在确定 GSK3β 抑制及其在脂多糖(LPS)诱导的急性肝衰竭(ALF)模型中机制的治疗潜力。
在 D-GalN(700mg/kg)/LPS(10μg/kg)诱导的小鼠 ALF 模型中,我们使用特定的化学抑制剂 SB216763 分析 GSK3β 机制,并检测内质网应激(ERS)的作用。分别在 D-GalN/LPS 注射前 2 小时或后给予 SB216763,然后在 D-GalN/LPS 处理后 6 小时处死小鼠,以评估其预防和治疗作用。分别评估死亡率、肝损伤、ERS、细胞因子表达、MAP 激酶、肝细胞凋亡和 TLR4 的表达。在体外研究 GSK3β 激活的抑制是否保护肝细胞免受 ERS 诱导的凋亡。
D-GalN/LPS 暴露后 GSK3β 迅速激活(去磷酸化)。给予 SB216763 不仅改善了肝损伤,表现为转氨酶水平降低,肝组织学结构良好,而且降低了死亡率。此外,GSK3β 抑制导致促凋亡蛋白 C/EBP 同源蛋白(CHOP)和半胱天冬酶-12 的下调,这与 ERS 有关。为了进一步证明 ERS 的作用,我们发现 GSK3β 抑制可保护肝细胞免受 ERS 诱导的细胞死亡。GSK3β 抑制下调 MAPK 途径,降低炎症细胞因子的表达,并降低 TLR4 的表达。
我们的研究结果表明,GSK3β 信号在 ALF 的病理生理学中具有关键作用,尤其是在调节 ERS 方面,并为靶向 GSK3β 作为改善 ALF 的潜在治疗策略提供了依据。